[go: up one dir, main page]

WO2008131858A3 - Verwendung acyclisch substituierter furopyrimidin-derivate zur behandlung der pulmonalen arteriellen hypertonie - Google Patents

Verwendung acyclisch substituierter furopyrimidin-derivate zur behandlung der pulmonalen arteriellen hypertonie Download PDF

Info

Publication number
WO2008131858A3
WO2008131858A3 PCT/EP2008/003007 EP2008003007W WO2008131858A3 WO 2008131858 A3 WO2008131858 A3 WO 2008131858A3 EP 2008003007 W EP2008003007 W EP 2008003007W WO 2008131858 A3 WO2008131858 A3 WO 2008131858A3
Authority
WO
WIPO (PCT)
Prior art keywords
pulmonary arterial
hypertonia
treating pulmonary
derivatives
acyclically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/003007
Other languages
English (en)
French (fr)
Other versions
WO2008131858A2 (de
Inventor
Thomas Lampe
Eva-Maria Becker
Raimund Kast
Hartmut Beck
Mario Jeske
Joachim Schuhmacher
Friederike Stoll
Martina Klein
Metin Akbaba
Andreas Knorr
Johannes-Peter Stasch
Lars Baerfacker
Alexander Hillisch
Gunter Karig
Mark Meininghaus
Karl-Heinz Schlemmer
Rudolf Schohe-Loop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Priority to CA002685128A priority Critical patent/CA2685128A1/en
Publication of WO2008131858A2 publication Critical patent/WO2008131858A2/de
Publication of WO2008131858A3 publication Critical patent/WO2008131858A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Anmeldung betrifft die Verwendung von acyclisch substituierten Furopyrimidin- Derivaten der Formel (I) zur Behandlung und/oder Prophylaxe der pulmonalen arteriellen Hypertonie und anderer Formen der pulmonalen Hypertonie sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe der pulmonalen arteriellen Hypertonie und anderer Formen der pulmonalen Hypertonie.
PCT/EP2008/003007 2007-04-26 2008-04-16 Verwendung acyclisch substituierter furopyrimidin-derivate zur behandlung der pulmonalen arteriellen hypertonie Ceased WO2008131858A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002685128A CA2685128A1 (en) 2007-04-26 2008-04-16 Use of acyclically substituted furopyrimidine derivatives for treating pulmonary arterial hypertonia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007019691.3 2007-04-26
DE102007019691A DE102007019691A1 (de) 2007-04-26 2007-04-26 Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie

Publications (2)

Publication Number Publication Date
WO2008131858A2 WO2008131858A2 (de) 2008-11-06
WO2008131858A3 true WO2008131858A3 (de) 2009-07-16

Family

ID=39777459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/003007 Ceased WO2008131858A2 (de) 2007-04-26 2008-04-16 Verwendung acyclisch substituierter furopyrimidin-derivate zur behandlung der pulmonalen arteriellen hypertonie

Country Status (3)

Country Link
CA (1) CA2685128A1 (de)
DE (1) DE102007019691A1 (de)
WO (1) WO2008131858A2 (de)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1817146A1 (de) * 1968-01-05 1969-11-27 Pfizer & Co C 4-Aminofuro[2,3-d]pyrimidine und deren Verwendung als Relaxantien fuer glatte Muskeln
EP1018514A1 (de) * 1998-07-22 2000-07-12 Suntory Limited Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten
WO2000075145A1 (en) * 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1132093A1 (de) * 1999-09-17 2001-09-12 Suntory Limited Vorbeugungsmittel oder heilmittel gegen myokarditis, dilatierte kardiomyopathie und herzinsuffiziens, die nf-kappa b inhibitoren als aktiven bestandteil enthalten
WO2002092603A1 (en) * 2001-05-14 2002-11-21 Novartis Ag Oxazolo-and furopyrimidines and their use in medicaments against tumors
WO2003022852A2 (en) * 2001-09-11 2003-03-20 Smithkline Beecham Corporation Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
WO2005092896A1 (en) * 2004-03-12 2005-10-06 Korea Institute Of Science And Technology Compound for inhibiting tyrosine kinase activity of ddr2 protein
WO2005121149A1 (en) * 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
WO2006004658A2 (en) * 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
WO2007079862A1 (de) * 2005-12-21 2007-07-19 Bayer Healthcare Ag Neue, acyclisch substituierte furopyrimidin-derivate und ihre verwendung zur behandlung von kardiovaskulären erkrankungen

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10141212A1 (de) 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
CA2470813A1 (en) 2001-12-20 2003-07-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
US7230017B2 (en) 2002-08-27 2007-06-12 Bayer Healthcare Ag Dihydropyridinone derivatives
WO2004024701A1 (en) 2002-09-10 2004-03-25 Bayer Healthcare Ag Heterocyclic derivatives
PL375647A1 (en) 2002-09-10 2005-12-12 Bayer Healthcare Ag Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
WO2005080372A1 (en) 2004-02-19 2005-09-01 Bayer Healthcare Ag Dihydropyridinone derivatives
WO2005082863A2 (en) 2004-02-26 2005-09-09 Bayer Healthcare Ag 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
ES2394177T3 (es) 2004-02-26 2013-01-23 Bayer Intellectual Property Gmbh 1,4-diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1817146A1 (de) * 1968-01-05 1969-11-27 Pfizer & Co C 4-Aminofuro[2,3-d]pyrimidine und deren Verwendung als Relaxantien fuer glatte Muskeln
EP1018514A1 (de) * 1998-07-22 2000-07-12 Suntory Limited Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten
WO2000075145A1 (en) * 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1132093A1 (de) * 1999-09-17 2001-09-12 Suntory Limited Vorbeugungsmittel oder heilmittel gegen myokarditis, dilatierte kardiomyopathie und herzinsuffiziens, die nf-kappa b inhibitoren als aktiven bestandteil enthalten
WO2002092603A1 (en) * 2001-05-14 2002-11-21 Novartis Ag Oxazolo-and furopyrimidines and their use in medicaments against tumors
WO2003022852A2 (en) * 2001-09-11 2003-03-20 Smithkline Beecham Corporation Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
WO2005092896A1 (en) * 2004-03-12 2005-10-06 Korea Institute Of Science And Technology Compound for inhibiting tyrosine kinase activity of ddr2 protein
WO2005121149A1 (en) * 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
WO2006004658A2 (en) * 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
WO2007079862A1 (de) * 2005-12-21 2007-07-19 Bayer Healthcare Ag Neue, acyclisch substituierte furopyrimidin-derivate und ihre verwendung zur behandlung von kardiovaskulären erkrankungen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 2002 (2002-11-01), GALIÈ NAZZARENO ET AL: "Emerging medical therapies for pulmonary arterial hypertension.", XP002528176, Database accession no. NLM12525997 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 2006 (2006-09-01), BRESSER PAUL ET AL: "Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.", XP002528177, Database accession no. NLM16963540 *
PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY SEP 2006, vol. 3, no. 7, September 2006 (2006-09-01), pages 594 - 600, ISSN: 1546-3222 *
PROGRESS IN CARDIOVASCULAR DISEASES 2002 NOV-DEC, vol. 45, no. 3, November 2002 (2002-11-01), pages 213 - 224, ISSN: 0033-0620 *

Also Published As

Publication number Publication date
CA2685128A1 (en) 2008-11-06
DE102007019691A1 (de) 2008-10-30
WO2008131858A2 (de) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2010057101A3 (en) Compounds useful as hiv blockers
MX2010006033A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso.
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
NO20091655L (no) Substituerte dihydropyrazoloner for behandling av kardiovaskulaere og hematologiske sykdommer
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008079291A3 (en) Substituted heterocycles and methods of use
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2008073933A3 (en) 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
WO2008076046A8 (en) Novel 2-amino-5, 5-diaryl-imidazol-4-ones
WO2009145456A3 (ko) 헤테로사이클 유도체
WO2009026179A3 (en) Antiinfective proanthocyanidin compounds and methods of use thereof
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
TW200738651A (en) Cyclohexyl sulfonamide derivatives
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
MY150702A (en) Substituted 4-phenyltetrahydroisoquinonelines, method of producing them, their use as medicament, and also medicament containing them
TW200621765A (en) Substituted phenylaminothiazoles and their use
WO2009124962A3 (en) Sulfonamides
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
MX2009001315A (es) Compuestos de dimetilciclobutilo substituidos, su preparación y uso en medicamentos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08735262

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008735262

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2685128

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010504501

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP